Act A — The Subspecialty Question
Hilar cholangiocarcinoma — bile duct cancer at the junction of the hepatic ducts — is one of the most technically demanding operations in hepatopancreatobiliary surgery. The resectability assessment requires understanding the tumour's relationship to the portal vein, the hepatic artery, and the biliary system in three dimensions, typically from cross-sectional imaging. The decision between resection, biliary drainage, and systemic management depends on factors that require subspecialty expertise to evaluate.
Dr. Amara is a capable general surgeon with genuine technical skill. He has managed a high volume of abdominal surgery, including hepatobiliary cases. He is not an HPB subspecialist. When he sees a case that exceeds the subspecialty boundary of his training, he knows it — and he knows that the patient's outcome depends on whether he can access the subspecialty knowledge that he does not hold.
In Freetown, that subspecialty knowledge is not available in-house. His question is whether it is available remotely, to a surgeon who can engage as a peer and provide a structured clinical opinion.
Act B — The Story
Dr. Amara submitted a case consultation request to the MarketForge surgical consultation platform. His documentation package: CT scan images in DICOM format, operative exploration findings from an initial diagnostic laparoscopy, CA 19-9 serum levels, patient age and performance status, and his clinical question: assess Bismuth–Corlette classification and resectability; second opinion on management approach.
His request was matched to Dr. Chen, an HPB surgeon at the University Health Network in Toronto who had registered as a volunteer consultant on the platform three months earlier. Dr. Chen's subspecialty profile listed hepatobiliary surgery as his primary practice, with specific experience in hilar cholangiocarcinoma assessment and management.
Dr. Chen reviewed the DICOM images and the case documentation over the following 48 hours. His written consultation report addressed the Bismuth–Corlette classification (Type IIIa, based on the imaging), the resectability assessment (portal vein involvement making R0 resection uncertain at high risk), and — the point that changed Dr. Amara's management plan — a third option Dr. Amara had not fully considered: percutaneous transhepatic biliary drainage as a palliative approach, combined with gemcitabine-based chemotherapy, which current evidence supports as equivalent in survival outcomes to incomplete resection for this staging, without the surgical mortality risk in a patient whose performance status made major hepatic resection high-risk.
Dr. Amara's original plan had been weighing resection against simple biliary stenting. Dr. Chen's consultation introduced the current evidence base for the combined palliative approach, and pointed Dr. Amara toward the specific drainage technique most appropriate for a Type IIIa anatomy.
The management plan was revised.
Act C — Why This Market Stays Broken Without Infrastructure
Dr. Chen consults on cases like this in Toronto's Tumour Board every three weeks. His knowledge of the current evidence base, and his ability to translate that evidence into a management recommendation for the specific imaging findings, is the same whether the case is in Toronto or Freetown. The consultation he provided to Dr. Amara is not substantively different from the consultation he provides to a surgical resident who presents an HPB case at rounds.
The barrier was not capability — it was discoverability. Dr. Amara could not find Dr. Chen. Dr. Chen's willingness to consult on cases remotely was not signalled in any channel Dr. Amara could access. The structured engagement framework — the documentation protocol, the advisory-basis clarity, the DICOM transfer — resolved the logistics that make informal remote consultation too uncertain to rely on.
Thin market infrastructure makes the subspecialty consultation need visible to the subspecialty practitioner who can serve it — providing access to the peer consultation that developed-world surgeons use as a matter of course, without requiring a personal relationship that has to be built before the case arrives.
Characters are fictional. Hilar cholangiocarcinoma Bismuth–Corlette classification, percutaneous transhepatic biliary drainage, and current evidence on resection vs. palliative management are real. DeeperPoint is building the infrastructure this story describes.